The objective of this randomized, single-dose, two-way crossover evaluation is to compare the
relative bioequivalence of a test azithromycin formulation (TEVA Pharmaceuticals USA) to an
equivalent oral dose of the commercially available azithromycin (Zithromax®, Pfizer, Inc.) in
a test population of 24 adult subjects under fed conditions.